It has been shown that a concomitant benefit of inhibiting SGLT2 in type 2 diabetes is lowering blood pressure,63,64,65 possibly from hemodynamic changes in kidney glomeruli66 and regulating the renin-angiotensin-aldosterone system.67 The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.